Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Fevipiprant

    ACTIVE PHARMA INGREDIENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Gossamer Bio's DP2 inhibitor GB001 fails 2 midphase trials
    Gossamer Bio's DP2 inhibitor GB001 fails 2 midphase trials

    14 Oct 2020

    // Nick P.Taylor FIERCE PHARMA

    https://www.fiercebiotech.com/biotech/gossamer-bio-s-dp2-inhibitor-gb001-fails-2-midphase-trials

    Nick P.Taylor FIERCE PHARMA
    14 Oct 2020
    Share Share
    Novartis dumps asthma program after another set of phase 3 flops
    Novartis dumps asthma program after another set of phase 3 flops

    16 Dec 2019

    // Nick Paul Taylor FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/novartis-dumps-asthma-program-after-another-set-phase-3-flops

    Nick Paul Taylor FIERCE BIOTECH
    16 Dec 2019
    Share Share
    Novartis' asthma drug fails in phase 3
    Novartis' asthma drug fails in phase 3

    22 Oct 2019

    // Nick Paul Taylor FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/novartis-asthma-drug-fails-phase-3-raising-doubts-about-gossamer-s-prospects

    Nick Paul Taylor FIERCE BIOTECH
    22 Oct 2019
    Share Share
    Novartis CEO Vas Narasimhan lines up his late-stage blockbuster contenders
    Novartis CEO Vas Narasimhan lines up his late-stage blockbuster contenders

    06 Nov 2018

    // John Carroll ENDPTS

    https://endpts.com/novartis-ceo-vas-narasimhan-lines-up-his-late-stage-blockbuster-contenders-mixing-old-favorites-and-add-ons/

    John Carroll ENDPTS
    06 Nov 2018
    Share Share